| Literature DB >> 34907064 |
Christian A Brünahl1,2, Susanne G R Klotz3,4, Gesche Ketels4, Bernd Löwe3, Christoph Dybowski3, Rebecca Albrecht3, Johanna Höink5, Margit Fisch2.
Abstract
OBJECTIVE: To explore feasibility in terms of delivering and evaluating a combination of physiotherapy and psychotherapy for patients with chronic pelvic pain syndrome (CPPS).Entities:
Keywords: clinical trials; interstitial cystitis; pain management
Mesh:
Year: 2021 PMID: 34907064 PMCID: PMC8671982 DOI: 10.1136/bmjopen-2021-053421
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Flow of participants. CPPS, chronic pelvic pain syndrome; SF-12: 12-Item Short-Form Health Survey.
Comparison of demographic and clinical characteristics at baseline
| Variable | Intervention group (n=36) | Control group (n=24) | P value |
| Demographic characteristics | |||
| Female, % (n) | 52.8 (19) | 58.3 (14) | 0.67* |
| Age in years, mean (SD) | 48.6 (±14.8) | 50.6 (±14.5) | 0.60† |
| Marital status, % (n)‡ | (n=35) | (n=22) | 0.29§ |
| Single | 37.1 (13) | 27.3 (6) | |
| Married | 37.1 (13) | 45.5 (10) | |
| Divorced | 25.7 (9) | 18.2 (4) | |
| Other | 0 | 9.1 (2) | |
| Educational level, % (n)‡ | (n=28) | (n=20) | 0.13§ |
| 6 years of secondary school | 14.3 (4) | 20.0 (4) | |
| 8 years of secondary school | 28.6 (8) | 55.0 (11) | |
| High school graduation | 53.6 (15) | 25.0 (5) | |
| Other | 3.6 (1) | 0 | |
| Pain duration in years, mean (SD) | 6.2 (4.8) | 6.2 (4.8) | 0.98† |
| Psychometric assessments, mean (SD) | |||
| 7.9 (5.5) | 6.5 (5.1) | 0.33† | |
| 23.4 (13.6) | 22.9 (16.1) | 0.90† | |
| 26.7 (15.2) | 26.6 (18.3) | 0.95† | |
| 9.9 (5.8) | 9.1 (6.9) | 0.65† | |
| 11.0 (5.0) | 10.3 (6.0) | 0.63† | |
| 0.5 (0.2) | 0.5 (0.2) | 0.78† | |
| 39.5 (8.5) | 38.0 (12.0) | 0.61† | |
| 39.9 (11.9) | 40.2 (11.1) | 0.93† | |
| 18.2 (9.4) | 18.6 (12.5) | 0.89† | |
| SF-MPQ sen. | 13.2 (7.1) | 14.6 (8.6) | 0.52† |
| SF-MPQ aff. | 5.0 (3.2) | 4.0 (4.2) | 0.33† |
| NIH-CPSI total | 24.1 (7.4) | 23.7 (7.6) | 0.83† |
| Pain subscale | 11.3 (3.8) | 11.4 (3.7) | 0.92† |
| Urinary subscale | 4.7 (2.9) | 4.1 (2.7) | 0.38† |
| QoL subscale | 8.0 (2.3) | 8.2 (2.7) | 0.85† |
*Χ2.
†t-test for independent samples.
‡Assessed at outpatient clinic visit (t1).
§Fisher’s exact test.
GAD-7, Generalised Anxiety Disorder Screener; NIH-CPSI, Chronic Prostatitis Symptom Index of the National Institutes of Health; PCS, Pain Catastrophizing Scale; PDI, Pain Disability Index; PHQ-9, Patient Health Questionnaire 9 (depressive symptoms); PSQ, Perceived Stress Questionnaire; QoL, Quality of Life; SF-12 MCS, 12-Item Short-Form Health Survey Mental Component Summary; SF-MPQ, Short-Form McGill Pain Questionnaire; SF-MPQ aff., affective subscale of Short-Form McGill Pain Questionnaire; SF-MPQ sen., sensory subscale of Short-Form McGill Pain Questionnaire; SF-12 PCS, 12-Item Short-Form Health Survey Physical Component Summary.
Treatment satisfaction
| All | Female | Male | Overall comparisons | ||||||
| Modules* | Sex | Modulessex* | |||||||
| N | Est. M (SE) | N | Est. M (SE) | N | Est. M (SE) | p (d) | p (d) | p (d) | |
| Overall treatment | 25 | 6.0 (0.2) | 14 | 5.9 (0.3) | 11 | 6.2 (0.3) | 0.08 (0.72) | 0.37 (0.38) | 0.89 (0.10) |
| Psychotherapeutic module | 25 | 5.4 (0.3) | 14 | 5.1 (0.4) | 11 | 5.6 (0.4) | |||
| Physiotherapeutic module | 25 | 5.9 (0.3) | 14 | 5.6 (0.4) | 11 | 6.1 (0.5) | |||
Items: ‘Would you recommend …?’ scale from 1 = ‘does not apply at all’ to 7 = ‘fully applies’; higher values correspond with higher treatment satisfaction.
*Overall treatment vs psychotherapeutic module versus physiotherapeutic module.
Est. M, estimated mean.
Post-treatment (t6) comparisons between the intervention group and the control group, adjusted for baseline (t2), sex, and the interaction of sex*group
| Outcome variable | Intervention group | Control group | Comparison | |||||||||
| n | Est. mean | SE | n | Est. mean | SE | Mean difference | ES | ES SE | ES CI 95% lower limit | ES CI 95% upper limit | P | |
| SF-12 PCS | 22 | 44.2 | 1.3 | 23 | 41.7 | 1.3 | 2.5 | 0.40 | 0.3 | −0.19 | 0.99 | 0.18 |
| SF-12 MCS | 22 | 42.8 | 1.9 | 23 | 41.4 | 1.9 | 1.4 | 0.15 | 0.3 | −0.43 | 0.74 | 0.61 |
| PDI | 22 | 18.4 | 2.3 | 22 | 26.5 | 2.4 | −8.1 | − | 0.3 | −1.34 | −0.12 |
|
| NIH-CPSI total | 22 | 18.6 | 1.5 | 23 | 20.8 | 1.5 | −2.2 | −0.31 | 0.3 | −0.90 | 0.28 | 0.30 |
| Pain subscale | 22 | 8.6 | 0.8 | 23 | 9.5 | 0.8 | −0.8 | −0.22 | 0.3 | −0.81 | 0.37 | 0.46 |
| Urinary subscale | 22 | 3.7 | 0.4 | 23 | 3.8 | 0.4 | −0.1 | −0.04 | 0.3 | −0.63 | 0.54 | 0.88 |
| QoL subscale | 22 | 6.4 | 0.5 | 23 | 7.5 | 0.5 | −1.2 | −0.50 | 0.3 | −1.10 | 0.09 | 0.10 |
| SF-MPQ total | 22 | 12.3 | 1.7 | 22 | 15.6 | 1.7 | −3.2 | −0.40 | 0.3 | −1.00 | 0.20 | 0.19 |
| SF-MPQ sensory | 22 | 9.7 | 1.2 | 22 | 11.2 | 1.2 | −1.5 | −0.27 | 0.3 | −0.86 | 0.33 | 0.38 |
| SF-MPQ affective | 22 | 2.7 | 0.6 | 22 | 4.2 | 0.6 | −1.5 | −0.55 | 0.3 | −1.16 | 0.05 | 0.08 |
| PCS | 22 | 14.7 | 1.8 | 22 | 19.5 | 1.8 | −4.8 | −0.56 | 0.3 | −1.17 | 0.04 | 0.07 |
| PHQ-9 | 22 | 6.9 | 0.9 | 22 | 9.5 | 0.9 | −2.6 | − | 0.3 | −1.23 | −0.02 |
|
| GAD-7 | 22 | 5.7 | 0.9 | 22 | 6.5 | 0.9 | −0.9 | −0.21 | 0.3 | −0.81 | 0.38 | 0.48 |
| PHQ-15 | 22 | 9.9 | 0.8 | 21 | 9.8 | 0.8 | 0.2 | 0.04 | 0.3 | −0.56 | 0.64 | 0.89 |
| PSQ | 22 | 0.4 | 0.0 | 22 | 0.5 | 0.0 | −0.0 | −0.14 | 0.3 | −0.74 | 0.45 | 0.64 |
P values <0.05 and corresponding ES are presented in bold.
ES, effect size Cohens’ d; ES CI, CI interval of the effect size; ES SE, SE error of the effect size; Est., estimated; GAD-7, Patient Health Questionnaire Generalized Anxiety Disorder Screener; NIH-CPSI, National Institutes of Health Chronic Prostatitis Symptom Index; PCS, Pain Catastrophizing Scale; PDI, Pain Disability Index; PHQ-9, Patient Health Questionnaire 9 (depressive symptoms); PHQ-15, Patient Health Questionnaire 15 (severity of somatic symptoms); PSQ, Perceived Stress Questionnaire; QoL, Quality of Life; SF-12 MCS, 12-Item Short-Form Health Survey Mental Component Summary; SF-MPQ, Short-Form McGill Pain Questionnaire; SF-MPQ affective, affective subscale of the Short-Form McGill Pain Questionnaire; SF-MPQ sensory, sensory subscale of the Short-Form McGill Pain Questionnaire; SF-12 PCS, 12-Item Short-Form Health Survey Physical Component Summary.
Sex-dependent post-treatment (t6) comparisons between the intervention group and the control group
| Outcome variable | Female patients | Male patients | Overall | ||||||||||||||||
| Intervention group | Control group | Comparison | Intervention group | Control group | Comparison | ||||||||||||||
| n | Est. mean | SE | n | Est. mean | SE | Mean diff. | ES | n | Est. mean | SE | n | Est. mean | SE | Mean diff. | ES | ES diff. | P main effect sex | P interaction sex*group | |
| SF-12 PCS | 10 | 45.6 | 1.9 | 14 | 43 | 1.6 | 2.6 | 0.44 | 12 | 42.7 | 1.7 | 9 | 40.4 | 2 | 2.3 | 0.39 | 0.05 | 0.13 | 0.94 |
| SF-12 MCS | 10 | 41 | 2.9 | 14 | 39.9 | 2.4 | 1.1 | 0.12 | 12 | 44.6 | 2.6 | 9 | 42.8 | 3 | 1.8 | 0.2 | −0.08 | 0.24 | 0.9 |
| PDI | 10 | 18.8 | 3.5 | 13 | 26.4 | 3 | −7.6 | −0.69 | 12 | 18 | 3.2 | 9 | 26.6 | 3.7 | −8.6 | −0.79 | 0.09 | 0.92 | 0.88 |
| NIH-CPSI total | 10 | 19.5 | 2.2 | 14 | 19.9 | 1.9 | −0.4 | −0.05 | 12 | 17.7 | 2 | 9 | 21.8 | 2.3 | −4.1 | −0.59 | 0.53 | 0.97 | 0.38 |
| Pain subscale | 10 | 8.9 | 1.2 | 14 | 8.9 | 1 | 0 | 0.01 | 12 | 8.3 | 1.1 | 9 | 10 | 1.2 | −1.7 | −0.46 | 0.47 | 0.78 | 0.44 |
| Urinary subscale | 10 | 4.3 | 0.7 | 14 | 3.9 | 0.6 | 0.4 | 0.2 | 12 | 3 | 0.6 | 9 | 3.7 | 0.7 | −0.6 | −0.29 | 0.5 | 0.23 | 0.41 |
| QoL subscale | 10 | 6.4 | 0.7 | 14 | 7.1 | 0.6 | −0.8 | −0.34 | 12 | 6.3 | 0.7 | 9 | 7.9 | 0.8 | −1.6 | −0.68 | 0.34 | 0.61 | 0.58 |
| SF-MPQ total | 10 | 12.5 | 2.5 | 13 | 15.6 | 2.2 | −3.1 | −0.39 | 12 | 12.2 | 2.3 | 9 | 15.6 | 2.6 | −3.4 | −0.43 | 0.04 | 0.93 | 0.94 |
| SF-MPQ sensory | 10 | 10.4 | 1.8 | 13 | 11.3 | 1.6 | -1 | −0.17 | 12 | 9.1 | 1.6 | 9 | 11.2 | 1.9 | −2.1 | −0.37 | 0.2 | 0.66 | 0.74 |
| SF-MPQ affective | 10 | 2.4 | 0.9 | 13 | 4.2 | 0.7 | −1.8 | −0.67 | 12 | 3 | 0.8 | 9 | 4.3 | 0.9 | −1.3 | −0.47 | −0.2 | 0.66 | 0.75 |
| PCS | 10 | 12.6 | 2.7 | 13 | 19.7 | 2.3 | −7.2 | −0.86 | 12 | 16.8 | 2.4 | 9 | 19.2 | 2.8 | −2.4 | −0.29 | −0.57 | 0.48 | 0.37 |
| PHQ-9 | 10 | 6.9 | 1.3 | 13 | 10 | 1.1 | −3.1 | −0.75 | 12 | 6.9 | 1.2 | 9 | 9 | 1.4 | −2.1 | −0.52 | −0.23 | 0.7 | 0.7 |
| GAD-7 | 10 | 5.5 | 1.3 | 13 | 5.5 | 1.1 | 0 | 0 | 12 | 5.8 | 1.1 | 9 | 7.5 | 1.3 | −1.7 | −0.43 | 0.43 | 0.38 | 0.48 |
| PHQ-15 | 10 | 10.3 | 1.1 | 12 | 9.7 | 1 | 0.6 | 0.18 | 12 | 9.5 | 1 | 9 | 9.8 | 1.2 | −0.3 | −0.09 | 0.27 | 0.74 | 0.67 |
| PSQ | 10 | 0.4 | 0 | 13 | 0.5 | 0 | 0 | −0.29 | 12 | 0.5 | 0 | 9 | 0.5 | 0 | 0 | 0 | −0.29 | 0.8 | 0.64 |
diff., difference; ES, effect size Cohen’s d; Est., estimated; GAD-7, Patient Health Questionnaire Generalized Anxiety Disorder Screener; NIH-CPSI, National Institutes of Health Chronic Prostatitis Symptom Index; PCS, Pain Catastrophizing Scale; PDI, Pain Disability Index; PHQ-9, Patient Health Questionnaire 9 (depressive symptoms); PHQ-15, Patient Health Questionnaire 15 (severity of somatic symptoms); PSQ, Perceived Stress Questionnaire; QoL, Quality of Life; SF-12 MCS, 12-Item Short-Form Health Survey Mental Component Summary; SF-MPQ, Short-Form McGill Pain Questionnaire; SF-MPQ affective, affective subscale of the Short-Form McGill Pain Questionnaire; SF-MPQ sensory, sensory subscale of the Short-Form McGill Pain Questionnaire; SF-12 PCS, 12-Item Short-Form Health Survey Physical Component Summary.
Figure 2Course of important outcome variables in the intervention and the control group. SF-12 PCS, 12-Item Short-Form Health Survey Physical Component Summary; SF-12 MCS, 12-Item Short-Form Health Survey Mental Component Summary; PDI, Pain Disability Index; NIH-CPSI, National Institutes of Health Chronic Prostatitis Symptom Index; PHQ-9, Patient Health Questionnaire 9; PCS, Pain Catastrophizing Scale.